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in Gynecological Cancer
Albert Biete, Angeles Rovirosa and Gabriela Oses
Abstract
Gynecological malignancies, mainly cervical uterine cancer, continue to pres-
ent a high number of pelvic and para-aortic recurrences. Intraoperative radiation 
therapy (IORT) allows a precise therapeutic boost in the surgical bed in the cases 
in which removal of the tumor relapse is feasible. At the same time, IORT permits 
the exclusion of the radiosensitive organs from the irradiation field. While the first 
published gynecological IORT took place in 1905, the number of patients per year 
became stable and the published series are retrospective and limited. Recurrences 
are located in different areas with non-homogeneous prognostic and most of the 
published manuscripts are retrospective including a mix of primaries, sites and dif-
ferent types and results of salvage surgery. We have revised the present knowledge 
in this field and the main conclusion is that IORT increases the local control and, 
in selected cases, probably slightly the survival. Also, the quality of life is probably 
increased. Randomized trials that allow a breakthrough in the conclusions are 
highly unlikely to be performed in recurrent gynecological malignancies.
Keywords: gynecological cancer, radiotherapy, intraoperative radiation therapy, 
uterine cancer, ovarian cancer, endometrial cancer
1. Background
Intraoperative radiation therapy (IORT) is a boosting technique that delivers a 
single high dose fraction of radiation directly to the resection bed during surgery. 
The purpose is to selectively irradiate anatomical areas that have been identified 
as high risk of persistence of subclinical disease or even macroscopic unresect-
able residual disease. This identification is easily achieved by the direct vision of 
the area of interest through the surgical field. At the same time, IORT protects or 
avoids damage to surrounding structures or organs at risk (OAR) because they 
are radiosensitive. This allows good protection of pelvic organs, such as urinary 
bladder, ureter, rectum, bowel, etc., and, consequently, decreases the incidence 
of secondary undesired effects including enteritis, proctitis or cystitis. IORT can 
be delivered using a dedicated linear accelerator producing electron beams of 
different energies and penetration degrees, X-ray sources delivering low-energy 
radiation or high dose-rate brachytherapy sources. All of them can also be conve-
niently used for IORT procedures in primary or recurrent gynecological tumors. 
All techniques have different advantages and disadvantages. In the initial period, 
conventional radiotherapy linear accelerators were used, which meant that the 
patient had to be moved from the operating room to the radiotherapy room, which 
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was sometimes far away. Apart from inconveniences to transfer the patient at the 
time of surgery, there was also a risk of infections and a substantial prolongation 
of surgery time. As a result, compact mobile electron accelerators were designed 
that could be installed in a radio-protected operating room to avoid patient transfer 
(Mobetron and LIAC are the best known). Low kilovoltage X-ray tubes, such as 
Intrabeam, have a more specific design for intraoperative breast radiotherapy and 
do not have collimators of sufficient diameter. Another added difficulty is that the 
irradiation time is too long, about 20–40 minutes as compared to a few minutes in 
electron accelerators. Also, several dosimetric considerations are favoring the use 
of accelerated electron beams over 50 kV X-ray beams, the description of which is 
out of the scope of this chapter.
In the Radiation Oncology literature, the first description of an IORT procedure 
has been consistently attributed to Beck [1] but Casals et al. [2] from Barcelona 
documented a case of an IORT treatment in the gynecological area some years 
before. Comas and Prio [3] reported the case of a 33-year-old woman diagnosed 
with a cervical squamous cell carcinoma treated by radical surgery and intrapelvic 
roentgen therapy to the left parametria. The patient survived at least 6 years after 
the treatment was completed (Figure 1). Results were very limited for much of 
the century, but through the introduction of megavoltage linear accelerators and 
later specifically designed units as previously explained, studies of IORT delivery 
procedures began to be published.
IORT has been used in the primary management, as well as in the salvage set-
ting, for many solid tumors of different locations. Conservative treatment of breast 
cancer has been the most common indication, but many treatments have been done 
in other sites such as the pancreas, the rectum, the cardio-esophageal junction, etc.
Figure 1. 
Original picture of the first published IORT treatment. The patient was irradiated to the distant parametrial 
area and survived at least 7 years. Drs. C. comas and A. Prio signed the image. Barcelona, 1905.
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Two reviews on IORT in gynecological tumors have been previously published. 
The first one, from Backes and Martin [4], comprises all gynecological malignan-
cies, including separate sections focused on uterine primary tumors and recurrent 
cervical cancer. A total amount of 276 cases of cervical cancer (primary and recur-
rent) were collected. The main conclusion is that if the surgical margins are positive 
or close, IORT appears to increase local control of the disease, with an acceptable 
toxicity profile. The second review, recently published by Krengly et al. [5], focuses 
on endometrial, cervical, renal, bladder and prostate cancers. A total of 153 patients 
(primary and recurrent cervical cancer) from 4 studies are analyzed in detail. They 
conclude as follows: in recurrent cervical cancer from these studies, it emerged that 
the status of the margins is the most important risk factor for treatment and the 
association of IORT seems to improve the probability of local control. In contrast, 
they do not recommend surgery and IORT for primary tumors. They state: “The 
available data suggests that this aggressive strategy is not advantageous in particular 
for the risk of severe side effects and that concomitant radio-chemotherapy alone 
should be considered the best treatment strategy in this patient setting.”
2. Biological and technical considerations
IORT using a linear accelerator of mobile electrons is given by applying a set of 
collimators of different diameters to the area of interest. The distal end may be per-
pendicular to the longitudinal or oblique axis, facilitating access to areas in the pel-
vic wall. The rotation of the accelerator head makes it easier to adapt the collimator 
to the area to be irradiated. If a risk organ cannot move out of the irradiation field, 
it can be protected by a metal disc, which is interposed between it and the radiation 
beam. The available accelerated electron energies are in a range of 4–12 MeV and 
the available collimator diameters are between 4 and 8 cm. The electron beams 
deposit their energy to a depth between 1.5 and 4 cm depending on the energy used. 
The dose refers to the 90% isodoses and from the determined depth falls sharply, 
which protects the organs located deeper. IORT can also be given employing Ir-192 
thread brachytherapy, but it is a more complex procedure and requires more time, 
and radioprotection, as well as the surface dose/dose ratio at the desired depth, is 
more unfavorable (Figure 2).
The carcinogenic effect depends not only on the nature of the radiation but also 
on the total dose and the time in which it is given (relative biological efficacy, RBE). 
The conventional dose per session in external pelvic radiotherapy is 1.8–2 Grays 
(Gy). In IORT, the doses usually used are 10–20 Gy and it is estimated that the RBE 
of this single large dose is equivalent up to 2–3 times the dose if delivered as stan-
dard external beam radiotherapy. Consequently, IORT can deliver more effective 
radiotherapy than an external beam, because the antineoplastic efficacy is strongly 
related to the dose.
Also, there is probably an extra benefit coming from diminishing the release 
of cell growth-stimulating cytokines. This has been well reported by Belletti et al. 
[6] in 2008 and later by Zaleska et al. [7] in 2016. It was shown that the growth of 
cell cultures of breast cancer lines could be stimulated by adding the fluid collected 
from the operative field to cell cultures. By contrast, if the fluid was collected 
after irradiation of the surgical site, no such stimulus was elicited. This may help 
to explain the high effectiveness of IORT in preventing tumor recurrence in the 
treated area. Also, it has been shown that irradiation blocks the proliferative cascade 
induced by surgical wound repair. Moreover, Zaleska et al. [7] showed that inhibi-
tion patterns vary according to the different histological types of breast cancer, with 
maximum inhibition in the luminal subtypes.
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3. Intraoperative radiotherapy in locally advanced cervical cancer
The elective treatment in advanced cervical cancer is simultaneous radioche-
motherapy followed by brachytherapy plus/minus parametrial depending on the 
extend of the tumor after chemoradiation. Nevertheless, in some cases, brachyther-
apy could not be performed and then these patients could be treated using SBRT 
(Stereotaxic radiotherapy) techniques but with lower results in comparison to the 
elective treatment. Although in 2/3 of the patients the clinical results are satisfac-
tory, there are some cases in which the tumor remains out of control. IORT has been 
considered a novel approach after the removal of the persistent tumor to boost with 
irradiation of the surgical bed at risk and mainly performed in FIGO stages IIB.
Martinez-Monge et al. [8] described in 31 patients the results of IORT after 
surgery in resectable cervical cancer. These patients were treated from 1986 to 
1999 with cisplatin plus fluorouracil chemotherapy simultaneously with pelvic 
irradiation (dose: 45 Gy). After tumor removal, IORT was delivered to the risk 
areas [mainly pelvic sidewalls with a median dose of 12 Gy (range between 10 
and 25 Gy)]. Patients were irradiated using electrons of 9 or 12 MeV and the 
median field size was 6.4 cm (range between 5 and 12 cm). The 10-year local 
control obtained in the irradiation field was 92.8% and the pelvic control 78.6%. 
Attributable to IORT, toxicity was found in 14% of the patients manifested as 
transient pelvic pain and only one patient had neuropathy. The authors consid-
ered IORT as a boosting technique feasible and valuable in advanced resectable 
cervical tumors.
Giorda et al. [9] reported the results of a phase II trial in 42 patients that 
underwent surgery (radical hysterectomy) after 6–8 weeks of simultaneous 
Figure 2. 
Operating room designed for IORT and equipped with a mobile electron linear accelerator (LIAC). Hospital 
clinic. The University of Barcelona.
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chemotherapy and pelvic irradiation (50.4 Gy, 1.8 Gy/fraction). After the patho-
logical study, only 5/35 (23%) of the patients achieved a complete response and 
gross macroscopical disease was present in 10/35 (26%) patients. After tumor 
removal, IORT was administered in 83% of the patients to parametria (82%), pelvic 
sidewalls, obturator fossa, iliac vessels, macroscopic residual tumor or macroscopic 
lymph nodes. IORT median given dose was 11 Gy (range between 10 and 15 Gy), 
being the median field size diameter 6.3 cm (range from 5.7 to 8.3 cm). At 5 years, 
the overall survival (OS) was 49% and the disease-free survival (DFS) was 46% 
with a median time to recurrence of 22 months. In this phase II trial, it was difficult 
to correlate the detected complications to IORT. Although the authors concluded 
that IORT was mainly effective in patients with a pathological complete response 
and in those with residual tumor limited to the cervix, this statement became very 
difficult to be demonstrated.
In a report from Foley et al. [10], 32 patients were treated with IORT after 
surgery over a period of 17 years (1994–2011) and 21 (65.6%) of them had a diag-
nosis of cervical cancer (locally advanced and recurrent cervical cancer). After 
surgery, 84.4% of the primary cervical cancer patients had microscopically positive 
margins. Patients were treated using electrons from IORT with a median dose of 
13.5 Gy (range 10–22.5 Gy). The higher doses were delivered in the patients with 
gross tumor persistence. The mean cone size was 6.6 cm with diameters ranging 
between 4 and 10 cm. The pelvic sidewall was treated in 59.4%, central pelvis in 
21.8% and para-aortic areas in 18.8%, respectively. Only one patient developed a 
grade 3 peripheral neuropathy and no other relevant complications were reported. 
The authors concluded on the usefulness of IORT after surgery in advanced cases 
and relapses from cervical cancer and remark the need for clinical trials to better 
analyze the benefit to add IORT to the surgery.
Gao et al. [11] reported the results of a series of 27 cases presenting a stage II 
cervical adenocarcinoma collected between 1999 and 2002. The rationale of the 
study was on the worse prognosis of this raising histological subtype. The patients 
underwent HDR (high dose rate) brachytherapy (overall dose of 12–14 Gy in 2 
applications) and followed 1–2 weeks thereafter by surgery (total hysterectomy 
and selective lymphadenectomy). IORT given dose was 18–20 Gy using 12 MeV 
electrons and the diameter of the treatment field size was 10–12 cm with the 
protection of bowels, sigma, rectum and bladder. The obturator nerve was also 
partially shielded. Positive or close surgical margins were found in 8 of 27 cases 
(29.6%). About 4–6 courses of cisplatin and 5-fluorouracil adjuvant chemotherapy 
were administered 2 weeks after the surgery. The 5-year overall survival and 
disease-free survival were 77.8 and 70.4%, respectively. With a mean follow-up of 
81 months, 2 patients developed local relapse (7.4%), but outside of the treatment 
field. The main complication was the peripheral neuropathy that appeared in 2 
patients (7.4%) at 8 and 17 months, respectively. The authors concluded that IORT 
was safe and feasible, achieving an optimal local control benefit in stage II patients. 
The same group published in 2002 [12] a previous study describing the results of 
delivering IORT as a boosting irradiation technique after tumor resection in stage 
IIB patients. The 5-year survival was 95% and they conclude that this approach 
is a new and effective therapy method for this stage, mainly in adenocarcinoma 
histology.
According to the authors’ conclusions, it is very difficult or perhaps near impos-
sible to asses if adding IORT to extensive surgery in cervical cancer stage II has any 
advantage. Improving the results of standard therapies is not easy because the high 
control rates obtained. Even with a randomized trial, a large number of cases would 
be mandatory to have good discrimination and to be sure of a real benefit. We do 
not think that a study like that will be planned in a short future.
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4. IORT in recurrent cervical cancer
Most of the IORT treatments in gynecological tumors have been performed 
in cervical cancer recurrences. The main locations of them are central pelvis 
(cervix or vaginal vault if previous radical hysterectomy), pelvic walls, para-
metria and nodal areas (pelvic or para-aortic). The IORT has been performed 
on the surgical bed after complete resection or over the remaining unresectable 
recurrence, mainly because of infiltration or adherence to vascular or other 
anatomical structures. Facing the optimal efficacy, the goal always will be to 
achieve a complete resection with surgical margin free (R0) or at least only 
microscopically invaded (R1). Clinical results became worse if residual gross 
tumor remains after surgery.
When we made a short review of published clinical data on IORT in cervical 
cancer recurrences, we found that all studies are retrospectives series. The recruit-
ment periods are very long, with a low year rate and large heterogeneity in doses, 
irradiation fields, energies and duration of follow-up.
One of the historical series was published in 1997 by Garton et al. [13] from the 
Mayo Clinic. In a large group of 449 patients treated with IORT, 39 patients had 
gynecological tumors and 22 were cervical relapses. The median dose administered 
was 17.5 Gy (range 10– 25 Gy) and its variation was due to the different degrees of 
surgical radicality and tumor persistence (R0, R1 or R2). Most of the irradiated 
locations were lymph nodes followed by the pelvic wall. In a few cases, both sites 
were treated simultaneously. The 5-year actuarial local control rate on the irradi-
ated area was 81% but decreased to 67% if the whole pelvic and nodal areas were 
registered. The 5-year DFS was 40.5% mainly due to the appearance of distant 
metastasis. The authors concluded that the association of surgery, IORT and, if 
possible, external beam radiotherapy was the right therapeutic approach, but with 
an uncertain benefit of including IORT.
One of the largest trials on recurrent cervical cancer is the study by Mahe et al. 
[14]. Due to the short survival registered in these patients, they made a retrospec-
tive revision of IORT-treated cases. Between 1985 and 1993, a cohort of 70 patients 
presenting with pelvic recurrences underwent IORT with or without external radio-
therapy. The clinical series were collected from seven French institutions and results 
were reported in 1996. In most of the patients, the relapse location was on the pelvic 
sidewall (59/70) and central pelvis in the remaining patients. Lymph node relapses 
were not reported. Five patients underwent 100 kV X-rays IORT and electrons were 
used in the rest of the group. The median energy was 12 MeV (range 6–20 MeV) in 
R0/R1 cases and somewhat higher, 14 MeV (range 7–24 MeV), when macroscopic 
tumor persisted after surgery. The median IORT doses were similar (18–19 Gy) in 
both subgroups (R0/R1 vs. R2) but the broad range (10–30 Gy). The cone median 
diameter was 7.5 cm (range 4–9 cm). The median follow-up was 15 months and the 
5-year actuarial local control was 21%, with an OS of only 8%. This study reported 
one of the lowest local control and survival rates in the literature. Five of seventy 
patients (7.1%) developed late peripheral neuropathy, presenting with pain and 
paresthesia. The authors concluded that IORT seems feasible in recurrent cervical 
cancer but cannot dramatically improve prognosis.
A second paper from the Mayo Clinic was published some years later, in 2013, 
by Barney et al. [15]. The recruiting period was extended 9 years, with a total of 86 
patients treated between 1983 and 2010. Eight-five percent of patients had locally 
recurrent tumors and the remaining patients locally advanced primary cervical 
cancer. The most commonly performed surgery associated with IORT was pelvic 
exenteration (30%) followed by pelvic side wall resection (26%). In 20% of the 
patients, IORT was delivered to metastatic para-aortic nodes. During the surgical 
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procedure, 67% of the cases were found involving the pelvic sidewall but maximal 
debulking surgery was performed. Surgical margins were free (R0) in 41% of cases, 
microscopically involved (R1) in 35% and gross residual tumor (R2) in 24%. The 
patients underwent IORT with an electron beam from a conventional linear accel-
erator. The median given dose was 15 Gy (range 6–25 Gy) according to the resection 
margin (R0, R1 or R2). Site and R status were the parameters used to select the 
appropriate beam energies, and 9 and 12 MeV were the most commonly employed. 
In the previous study from the same institution [13], the median dose was a little 
higher (17.5 Gy vs. 15 Gy) and the irradiated volume slightly smaller in the present 
series. The authors considered that combining IORT and pelvic exenteration, the 
best results were achieved, improving the probability of local control. After sur-
gery, an R0 or R1 pathological result was obtained only in half of the patients, but 
the 3-year actuarial local control was 56%. Also, only 43% of patients underwent 
external beam irradiation after surgery. About IORT-related toxicity, 16/89 (18%) 
patients experienced peripheral neuropathy, 4/89 (4.5%) ureteral stenosis and also 
4.5% bowel perforation or fistula. We must point out that, keeping in mind that 
both studies from the Mayo Clinic share most of the patients, local control rates 
are rather different (70% at 5 years vs. 56% at 3 years). The authors concluded that 
long-term survival is possible with combined modality therapy including IORT for 
advanced and recurrences of cervical cancer, but distant relapse is common.
A Spanish study by Sole et al. [16] published in 2014 evaluated a series of 31 
patients with recurrent cervical cancer. Because all patients had undergone previous 
external irradiation, the management of relapse was limited to complete or debulk-
ing surgical resection and IORT. The mean electron given dose was 12.5 Gy (range 
10 to 15 Gy) and the median beam energy 12 Mev from a standard linear accelera-
tor. Circular cones most beveled ranged from 5 to 12 cm in diameter. The 5-year 
actuarial local control, OS and DFS were 65, 42, and 44%, respectively. Secondary 
effects directly associated with IORT were not reported. The authors concluded 
that patients presenting with local or nodal relapse were safely treated and had 
improved local control by adding IORT to the surgical resection. The largest benefit 
was detected in the R0 cases.
Tran et al. [17] conducted a study at Stanford University and reported the 
clinical results of a retrospective series of 36 consecutive patients treated from 1986 
to 2005. Cervical recurrent tumors were present in 17 (47%) patients, and all of 
them had negative margins (R0) on the perioperative pathological examination. 
IORT was delivered with an orthovoltage X-ray equipment (200–250 kV), using 
circular cones with diameters from 2.5 to 10 cm and bevels between 0° and 45°. 
Doses were referred to as the surface of the surgical bed. In some patients, custom-
ized lead shielding was designed to protect neighboring radiosensitive organs. The 
median dose given was 11.5 Gy (range 6–17.5 Gy). The 5-year actuarial local control 
was 45% and the DSF 46%. These results, which were more favorable than those 
reported elsewhere, should be interpreted taking into account that IORT was only 
administered in patients with R0 resections. Another explanation was the lower 
rate of sidewall pelvic location, 32% vs. 84% in the French study [16]. As previ-
ously commented on, recurrences on the pelvic sidewall have the worst prognosis 
compared with other sites such as the central pelvis or isolated metastatic lymph 
nodes. A very low reported rate of secondary effects due to IORT may be explained 
by shielding the organs at risk and limiting the peripheral nerve dose below 12.5 Gy. 
As a conclusion and remarking the importance of wisely selecting the candidates to 
IORT, the authors colloquially wrote: “It is a question of fishing in the right hole”.
A few years ago, in 2014, Backes et al. [18] published an article investigating 
whether the association of pelvic exenteration and IORT in recurrent gynecologi-
cal cancer could improve survival. A total of 21 patients out of 32 (65.6%) with 
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recurrence of cervical cancer underwent surgical resection and IORT. The median 
radiation dose was 17.5 Gy (range 10–20 Gy). The selected electron beam energy 
ranged from 6 to 12 MeV and the dose depth prescription was, as usual, at 90% 
isodose curve. In eight patients, the intraoperative radiation was delivered with 
HDR brachytherapy catheters. It is difficult to understand the results given only 
66% (21/32) of patients received IORT and the origin of the primary tumor (cervix, 
endometrium) was unclear. Probably the reason for that may be explained because 
the review has been focused to evaluate the efficacy of pelvic exenteration in 
the whole series. The 5-year actuarial local control rate differs according to the 
extension of surgery: pelvic exenteration and IORT (64%) vs. laterally extended 
endopelvic resection (69%). The authors’ conclusions remarked that IORT fails to 
ameliorate local control and survival outcomes. Nevertheless, the cohort treated 
with pelvic exenteration and IORT had a worse prognosis compared with patients 
treated only with pelvis lateral wall surgery. It would reasonable to conclude that if 
the local control rates are similar in both arms the addition of IORT may contribute 
to raising the local control in the worst prognosis subgroup.
To our knowledge, the most recent reported study on gynecological malig-
nancies treated with surgery and IORT is the German study of Arians et al. [19] 
published in 2016. This retrospective series included 36 patients, 18 (50%) of whom 
presented with cervical cancer recurrence. The recruitment period was 12 years 
(2002–2014). IORT was performed with a mobile linear accelerator delivering a 
range of electron beam energies between 6 and 18 MeV. Radiosensitive organs 
(bowel, ureters and peripheral nerves) were displaced out of the irradiated field or 
using radiation protection lead shields. The median given dose was 15 Gy (range 
10–18 Gy) and the median energy 8 MeV (range 6–15 MeV). The maximum dose 
permitted to the nerves was always below 10–12 Gy. With a median follow-up of 
14 months, the actuarial 5-year OS rate was 6.4% and the DFS 0%. The results of 
local control were even worse, with a rate of 0% at 2 years. The reported neural 
toxicity was 11%. Based on these unfavorable results, the authors concluded that 
surgical resection and IORT in cervical cancer recurrence should be considered a 
rather palliative procedure, suggesting a careful selection of patients to identify 
those who may benefit from this combined approach.
Our institutional experience is still limited and has been partially reported 
[20]. The IORT program started in 2013 with a mobile electron linear accelerator 
(LIAC) installed in a specifically designed operation room. Treatment objectives 
are mainly focused on conservative breast cancer but a series of patients with 
gynecological cancer recurrence have also been included as candidates to receive 
IORT. At present, 16 patients have been enrolled. Primary tumors included uterine 
cervix in 11 patients, uterine corpus in 4 and ovarian cancer in 1. The mean age was 
53 years (range 40–68). The most common histological type has been squamous cell 
carcinoma (10/16) followed by different types of adenocarcinoma (5/16) and one 
carcinosarcoma. Hysterectomy was performed in six cases, resection of local recur-
rence lesions in five and pelvic exenteration in five. A negative pathological margin 
(R0) was obtained in 9/16 cases, microscopically involved margins (R1) in 6/16 and 
macroscopic residual tumor in 1. IORT was administered to the surgical bed using 
an electron beam with energy ranges from 4 to 12 MeV and a mean diameter field 
of 5 cm (range 4–6). The median prescribed dose has been 11 Gy (range 8–15 Gy). 
We consider that beyond 15 Gy the probability of peripheral nerve damage is not 
acceptable. All the irradiated patients presented with pelvic recurrences (central in 
eight, the pelvic wall in four and both sites in four) but the involvement of para-
aortic nodes was also present in two patients. At follow-up, there were five cancer 
deaths and two patients were lost. Eight patients are in complete remission without 
any recurrence in the irradiated area. Only one marginal relapse has appeared.
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Taken all these data together, the difficulties of obtaining valid and objective 
conclusions should be emphasized. The heterogeneity of the data, size, location, 
and extent of the relapses, the different therapeutic approaches, IORT doses, differ-
ent surgical procedures, etc. must be taken into account before inadequate conclu-
sions. Probably, adding IORT to the debulking surgery may give an extra benefit 
in terms of local control, particularly if the resection is R0 or R1. But the influence 
on survival seems, if any, poor because of the high probability to develop pelvic 
carcinomatosis or distant metastasis.
5. Endometrial cancer
The experience with IORT in endometrial cancer is still more limited than in 
cervical cancer. Firstly, the pattern of recurrence is different, with very infrequent 
isolated relapses in the vaginal fundus fulfilling surgical indication. Most are usually 
controlled by external radiotherapy and brachytherapy. In other cases, the recur-
rence is in the form of peritoneal carcinomatosis, which already rules out combined 
management of surgery and IORT.
When reviewing the literature, it is observed that the majority of revisions do 
not include cases of endometrial cancer or do not allow their identification because 
they are mixed with the most numerous of the cervix or even vagina and vulva. For 
example, Solé et al. [16] in a series of 62 cases recruited over 17 years acknowledge 
that they have not included the origin of the primary tumor in the analysis criteria. 
In a subsequent article published 1 year later (2015) [21] dedicated specifically 
to IORT in oligometastases of gynecological cancer, it is surprising that it refers 
to more cases of endometrial than of cervical origin (18 vs. 14). With an average 
follow-up of 55 months, local control was 79% and DFS 44%, which stimulates the 
addition of IORT to external radiotherapy. In the multivariate analysis, surgery with 
a positive margin (R1) was the only independent prognostic factor. In a historical 
series of the Mayo Clinic, published in 1997 by Garton et al. [22] that includes 39 
gynecological neoplasms (recurrent or advanced), only 7 are primary endometrial 
tumors.
In the aforementioned review carried out by Backes et al. [4], 276 cases of 
cervical cancer with IORT from 8 institutions were collected, but there were only 
52 cases of endometrial cancer. This can be explained by the encouraging results of 
the primary treatment and even of the few isolated vaginal recurrences registered, 
which through a combination of external radiotherapy and brachytherapy reached 
control rates between 60% and 70%. Dowdy et al. [23] described a series of 25 
patients with recurrence of endometrial cancer treated by external radiotherapy, 
surgical resection and IORT. The probability of local control was 84% but dropped 
to 47% if residual tumor persisted. For this reason, they insisted on the need to 
achieve surgery with negative margins. The two cases with isolated para-aortic 
relapses achieved control of the disease. Awtrey et al. [24] in 2006, 26 months after 
that study of Dowdy et al. [23], published a second specific study of IORT and 
endometrial cancer.
One of the main difficulties to get any valid conclusion about the usefulness 
of IORT is the great disparity between different studies. Nowadays, endometrial 
cancer has a good prognosis in most of the treated cases. Recurrences are scarce and 
80% of them are located in the vaginal vault. Standard treatment of brachytherapy 
with or without external radiotherapy obtains satisfactory results. The cases that 
underwent surgery may benefit from the addition of IORT. The IORT published 
results in endometrium-isolated relapses are better than in cervical cancer and 
the toxicity is assumable if doses are under 15 Gy. We must keep in mind that a 
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significant number of patients will present later on peritoneal carcinomatosis and/
or lung metastasis, mainly the grade III tumors. Finally, it is slightly surprising that, 
in the cases presenting bad prognostic factors, IORT is not used more, because local 
control in endometrial cancer is mandatory.
6. Ovarian cancer
In most published studies, the cases of IORT in ovarian cancer are marginal and 
scarce, so that it is difficult to achieve any conclusions. As far as we are aware, there 
are only four relevant studies on the role of IORT in ovarian cancer.
One of the oldest series is that of Konski et al. [25] in 1990. They performed 
IORT on nine patients with recurrence of ovarian cancer and compared their evolu-
tion with a similar group without IORT. Survival was similar in both groups.
Yap et al. [26] present a series of 24 patients undergoing cytoreductive sur-
gery with which IORT was delivered to the areas at high risk of residual disease. 
Interestingly, IORT was given by using a 200 kV X-ray beam instead of an electron 
beam. The average dose was 12 Gy (range 9–14 Gy). At 2 years follow-up, only 5 
of the 24 patients were in complete remission, but only 5 showed relapse in the 
irradiated surgical bed, and the remaining relapse occurred in other areas. Because 
of the results, they concluded that IORT had some activity but its influence on the 
prognosis was very limited.
A more extensive series is the experience of Gao et al. [27] with 45 patients 
enrolled along 11 years (2000–2010) and undergoing cytoreductive surgery. IORT 
was performed on the pelvis using larger than usual fields (10–12 cm in diameter) 
and higher than usual doses, 18–20 Gy except in two cases with 10 Gy. They register 
local faults by 32% but the majority outside the irradiated field (10/14). The DFS 
was 55% at 5 years. The authors reported a rate of peripheral neuropathy of 11%, 
with an average time elapsed period of 11 months (range 8–22). They also register 
4% of hydronephrosis. It was concluded that IORT was effective in advanced 
cases or recurrences undergoing surgery, as well as it appears to discreetly increase 
survival and quality of life. Toxicity attributable to given doses greater than 15 Gy 
was not mentioned.
Barney et al. [28] from the Mayo Clinic published in 2011 a series of 20 cases 
treated between 1987 and 2009 because of relapses after surgery and chemo-
therapy. The IORT zones were pelvis (14/20), para-aortic (6/20) and inguinal 
fields. The average electron dose was 12.5 Gy (range 10–22.5 Gy). The probability 
of global-local control at 5 years was 59%, with 76% in the irradiated volume. In all 
cases of recurrence in the irradiation field, surgeries were R1. Survival at 5 years 
was 49%, similar to that in the previous study. Neural toxicity was recorded in 
three cases (15%).
Finally, Albuquerque et al. [29] reported a series of 27 localized extraperitoneal 
recurrences of ovarian cancer. In 17 cases (63%), surgical results R0 or R1 were 
obtained. At 5 years, the probability of local control in the irradiated area was 70% 
and DFS was 33%. It should be noted that in this series 37% of patients had macro-
scopic disease after surgery. The authors make a comparison with a similar group 
of relapsed patients treated only with surgery and chemotherapy without finding 
significant differences in survival, but they concluded “suggesting a role for locore-
gional therapies in selected patients presenting recurrences in ovarian cancer.”
The role and possible benefit of adding IORT to the surgical resection in ovarian 
cancers’ localized recurrences are still under debate. These kinds of recurrences, 
tumoral or nodal, are infrequent. Survival is not modified and probably the local 
control is more related to the quality of life. As we consider ovarian cancer as more 
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a systemic disease and focus more on systemic therapy, we can assess than IORT 
would have only a role in the scarce cases presenting an isolated and resectable 
pelvic recurrence.
7. Miscellaneous
In this section, we would like to comment briefly on three publications as a 
whole, in which no distinction has been made according to the origin of the gyneco-
logical neoplasia. The first one, from Coelho et al. [30], retrospectively analyzed 41 
patients with isolated or retroperitoneal recurrences of colorectal, gynecological or 
retroperitoneal primary tumors. Following salvage surgery, all patients underwent 
tumor bed IORT with an electron beam or brachytherapy. The median dose of IORT 
was 12 Gy. A total of 15 gynecological cancers (36%) were included, including 
tumors of the cervix in 8 cases, uterine corpus in 6 and ovary in 1. Patients were 
enrolled along 11 years, between 2004 and 2015, with a rate of 1.3 cases per year. 
The 5-year local control rate was 81%. Surgery R1 was the worst prognostic factor. 
Peripheral neural toxicity occurred in 7% of the cases.
Haddock et al. [31] reported the results of a retrospective series of 63 patients 
treated during a period of 12 years (1983–1995). The recruiting rate was 5.25 cases/
year. IORT was administered in 8 primary gynecological tumors and 55 relapses. 
Most of the patients (n = 40) had cervical cancer. There were 16 patients with 
tumors of the endometrium, 5 with vaginal and 2 with ovarian. Most patients had 
been previously treated with external beam radiotherapy. IORT was given with 
electrons with a range of energies between 9 and 18 MeV. When macroscopic 
residual persisted after surgery, the median dose administered was 20 Gy (R2) and 
15 Gy in R0-R1 cases. The actuarial 5-year local control was 74% but the probability 
to survive was 27%. The authors concluded that long-term disease control is obtain-
able in a significant number of carefully selected patients with locally advanced or 
recurrent gynecological malignancies with aggressive multimodality treatment, 
including IORT. Disease control was better when gross total resection was possible. 
Patients with local or regional relapse after previous external beam radiotherapy 
appeared to fare as well as those previously non-irradiated.
Finally, Gemignani et al. [32] reported a short series of 17 patients diagnosed 
with gynecological tumor recurrences. They were treated over a period of 5 years 
(1993–1998) with an inclusion rate of 3.4 cases per year, quite similar to our 
recruiting rate. Surprisingly, they are very young, with a median age of only 
49 years (range 27 to 72). The origin of neoplasms was the cervix in nine patients, 
the endometrium in seven and the vagina in one. R0-R1 surgical resections were 
obtained in 76% of cases and the median IORT dose was 14 Gy. The actuarial 3-year 
local control reached 67% but if gross tumor remains after surgery the local control 
decreased to 25%. In R0-R1 cases, the actuarial 3-year control was the highest, with 
an 85% rate, but the DFS rate was 54%. Peripheral neuropathy occurred in 18% of 
cases and ureteral stenosis in 12%. The authors concluded the need to obtain R0-R1 
surgical resections.
The results of different series obtained in clinical practice with the use of IORT 
in patients with gynecological cancer are shown in Table 1. Most of the experience 
comes from resected recurrences in various locations, mainly in the central pelvis. 
Cervical cancer is the most frequent diagnosis followed by endometrium and ovary. 
The most relevant published experience since 1995 includes 727 patients. The 
median number of patients per institution is 36, taking into account that the 70 
cases described by the French collaborative study [16] came from 7 institutions. The 
median given dose has been 14.8 Gy but with large differences (range between 27 
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and 6 Gy). We have divided all groups into two periods: 1995–2007 and 2008–2018. 
The median dose in the first period has been 15.5 Gy (range 6–27 Gy), whereas the 
median dose in the second period was 14.1 Gy (range 6–25 Gy). Differences are 
minor but a tendency to slightly lower doses is detected. The higher doses were 
administered when gross residual tumor persisted after surgery (R2) assuming 
that doses over 15 Gy increase the risk of peripheral neural toxicity and may cause 
ureteral stenosis and pelvic fibrosis if these structures are irradiated. However, in 
daily clinical practice, it is difficult to determine the precise cause of secondary 
effects: surgery, radiation or both. Broad differences in local control results are also 
registered. The probability to be free of the treated recurrence at 5 years switched 
around 30 and 100%, but most percentages are about 70–80%. No comparisons are 
allowed due to the high degree of heterogeneity among studies. Table 2 shows the 





5y OS 5y DFS 5y LC
1995 Stelzer et al. [33] 22 Recurrent 22 (14–27) 43% — 48%
1996 Mahe et al. [14] 70 Recurrent 18 (10–25) 8%(3y) — 30%
1997 Haddock et al. [31] 63 Mix 15 (8–25) 26% — 67%
1997 Garton et al. [13] 39 Mix 17 (10–25) 40% 32% 76%
2001 Martinez-Monge  
et al. [8]
36 Recurrent 15 14% 16% 42%
2001 Martinez-Monge  
et al. [8]
31 Primary-cervix 12 67% 70% 79%
2001 Gemignani  
et al. [32]
17 Recurrent 14 (12–15) 54% 3y 54% 3y 83% 3y
2002 Liu and  
Chen [12]
97 Primary-cervix 19 (18–20) 88% — —
2005 Yap et al. [26] 24 Recurrent-
ovary
12 (9–14) 22% — 68%
2006 Dowdy et al. [23] 25 Recurrent 15 (10–25) 71% — —
2007 Tran et al. [17] 36 Recurrent 11 (6–17) — 47% 44%
2011 Giorda et al. [9] 35 Primary-cervix 11 (10–15) 49% 46% 89%
2013 Gao et al. [27] 27 Primary-cervix 19 (18–20) 78% 70% 100%
2013 Barney et al. [15] 73 Recurrent 15 (6–25) — 31% 61%
2013 Barney et al. [15] 13 Primary-cervix 15 (6–25) — — 70%
2014 Foley et al. [10] 21 Recurrent 13.5 (10–22) 69% 30% 59%
2014 Backes and  
Martin [4]
21 Recurrent 17.5 (10–20) 30% — 59%
2015 Sole et al. [21] 61 Recurrent 12 (10–15) 42% 44% 65%
2016 Arians et al. [19] 36 Recurrent 15 (10–18) 22% — 44%
2018 Biete and Oses [20] 16 Recurrent 11 (8–15) 79% — 86%
2018 Coelho et al. [30] 15 Recurrent 12 (9–15) 56% — 81%
OS, overall survival; DFS, disease-free survival; LC, local control.
Table 1. 
Selected studies of the use of IORT for gynecologic malignancies.
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different recruiting rates from 18 studies, with a median study period of 10.7 years, 
although there is a large variation between a minimum of 5 years and a maximum 
of 27 years. The total number of cases included in this table is 626 and the median 
of cases per institution is 34.7 (range 15–86). The median recruitment rate is low 
(3.2 cases/year) and ranges between a maximum of 5.2 cases/year and a minimum 
of 1.4 cases/year. The previously cited French study raises a rate of 8.7 cases/year, 
but if we consider the 7 different institutions, then the rate lowers to 1.2 cases/year 
per hospital. Recruitment rates have been stable over the years, and also a strong 
heterogeneity in the published series persists.
8. Conclusions
The published studies on IORT have many parameters of heterogeneity. Some of 
them are as follows: recurrence sites of different prognosis such as pelvic sidewalls 
or central pelvic, margin status on resection (R0, R1 or R2), tumor initial and 
residual burden, high level of heterogeneity according to the different techniques, 
energies, fields, doses, etc. Even more, the conclusions of the referred studies are 
frequently different. It is not easy to demonstrate the efficacy and the benefit of 
IORT in these retrospective limited series. IORT is a radiation boost in a surgical 
procedure. In well-designed randomized prospective studies, it is frequently dif-
ficult to demonstrate the degree of local control benefit of postoperative radiother-
apy. This is particularly difficult in IORT because it is necessarily associated with 
different degrees of radicality in surgery, from local resection to pelvic exenteration 
or simply debulking.
Author Period Years N Rate/year
Coelho et al. [30] 2004–2005 11 15 1.4
Foley et al. [10] 1994–2011 17 32 1.9
Sole et al. [16] 1997–2012 15 35 2.3
Garton et al. [13] 1983–1991 8 39 4.9
Backes and Martin [4] 2000–2012 13 21 1.6
Arians et al. [19] 2002–2014 12 36 3.0
Tran et al. [17] 1986–2005 20 36 1.8
Giorda et al. [9] 2000–2007 8 42 5.2
Gao et al. [11] 1999–2006 7 27 3.8
Barney et al. [15] 1983–2010 27 86 3.2
Mahe et al. [14] 1985–1993 8 70 8.7
Gemignani et al. [32] 1993–1998 6 17 2.8
Garton et al. [22] 1981–1992 11 42 3.8
Martinez-Monge et al. [8] 1985–1992 8 26 3.2
Haddock et al. [31] 1983–1995 13 63 4.8
Dowdy et al. [23] 1986–2002 16 25 1.6
Yap et al. [26] 1994–2002 9 24 2.7
Biete and Oses [20] 2013–2017 5 16 3.2
Table 2. 
Recruitment period and year rate of different authors’ published studies.
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However, most of the referred studies agree that adding IORT to surgical resec-
tion is the right strategy for raising the local control rate. There are more doubts 
about the influence on survival and probably there is a little impact. Nevertheless, 
in cervical cancer, local control has a strong impact on the quality of life. We must 
keep in mind that half of the mortality in cervical cancer is due to a non-controlled 
pelvic disease.
By contrast, the therapeutic approach in primary tumors, including surgery and 
IORT, is strongly debated. It seems there is no clear advantage over the standard 
well-established approach, including chemoradiotherapy and brachytherapy. 
But there is some agreement that, if surgery is the therapeutic option, IORT is an 
effective tool adding extra safety and increasing the local control rate. Nevertheless, 
IORT is a therapeutical option still not included in the clinical guides.
Finally, we must point out the difficulty and the low probability to design and 
conduct randomized prospective trials. The experienced low accrual of enough 
number of patients in a reasonable time and the heterogeneity of recurrences and 
surgical procedures are hard difficulties to overcome.
9. Concluding remarks
Most of the published studies on IORT on gynecological cancer collected small 
and non-homogeneous series of patients with the additional difficulty of the long 
enrolment period. Cervical cancer, as primary or recurrence, is the most analyzed 
tumor, but many studies include a blend of recurrences from different sites: endo-
metrium, ovary and vagina. At the same time, there is a broad variety of recurrence 
locations: central pelvis, pelvic walls, retroperitoneal or pelvic nodes are the most 
common. There is also a great variation of the surgical radicality and margin status: 
R0, R1 or R2.
Nowadays, knowledge comes from retrospective and heterogeneous series. High 
survival achieved on the primary treatment, mainly in the cervix and endome-
trium, results in the onset of a few local recurrences. Then, candidates for IORT are 
scarce and the recruitment rate becomes low in all the institutions. On the other 
hand, IORT is not a standard option at the initial treatment. Even taken into account 
all the difficulties explained before, there is a broad consensus that IORT as a radia-
tion boost after salvage surgery adds an extra benefit to achieve better local control. 
Also, some authors assess that survival may also be slightly increased. There is no 
doubt about the benefit of IORT on quality of life. Even in patients presenting with 
the metastatic disease, local control is a valuable goal and has a substantial impact 
on the quality of life.
An important challenge for the future is the control of the tumor spreading in 
the peritoneal cavity, and in this case, the impact of the recurrence local control 
utilizing surgery and IORT would raise. Probably there will be in the near future 
little changes in IORT technique delivery excepting smaller units with better mobil-
ity and versatility. A significant increase in the treated patients’ rate is not expected, 
quite different from conservative breast cancer treatment.
Finally, the limited side effects of this radiation modality if doses do not exceed 
15 Gy must stick out. However, after nearly 30 years, IORT remains a technique of 
uneasy availability due to the limited number of institutions where it is available.
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